Skip to main content

Table 2 Relapse Input Values

From: Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

Parameter

Value

Data Source

Part A:

    

Relapse Rates Requiring Hospitalization – For Initial Relapse

Full Adherence

Partial Adherence

Non-Adherence

 

   Olanzapine

2.0%

3.6%

5.2%

 

   Risperidone

3.2%

5.8%

8.8%

Lieberman et al, 2005 [23];

   Quetiapine

4.9%

8.8%

14.0%

Gilmer et al, 2004 [16]

   Ziprasidone

4.2%

7.4%

11.6%

 

   Aripiprazole

4.2%

7.4%

11.6%

Assumed equal to ziprasidone

Relapse Rates Not Requiring Hospitalization

Full Adherence

Partial Adherence

Non-Adherence

 

   Olanzapine

2.0%

3.2%

4.8%

Lieberman et al, 2005 [23];

   Risperidone

3.2%

5.1%

7.9%

Gilmer et al, 2004 [16];

   Quetiapine

4.9%

7.8%

12.6%

Edwards et al, 2005 [18]

   Ziprasidone

4.2%

6.6%

10.5%

 

   Aripiprazole

4.2%

6.6%

10.5%

Assumed equal to ziprasidone

Part B:

    

Adjusted Relapse Rates Given a History of Relapse

Full Adherence

Partial Adherence

Non-Adherence

 

   Probability given history of 1 relapse

19%

40%

58%

 

   Probability given history of 2 relapses

36%

75%

100%

Olfson et al., 2000 [65];

Tiihonen et al., 2006 [66]

   Probability given history of 3 relapses

42%

88%

100%

 

Part C:

    

Probability of Suicide Event Given Adherence Level

Fully Adherent

Partially Adherent

Non-Adherent

 

   Probability of suicide attempt

0.25%

0.76%

1.00%

Ahn et al., 2007 [62]

   Probability suicide attempt is fatal

10.00%

Siris 2001 [60]

   Cost of non-fatal suicide attempt

$140 (in addition to relapse costs)

Assumption

   Cost of fatal suicide attempt

$0

Assumption